Posted by Michael Wonder on 20 Apr 2021
LEXEO Therapeutics announces FDA fast track designation granted to LX1001 for the treatment of APOE4 associated Alzheimer’s disease
20 April 2021 - LX1001 is the first investigational gene therapy being evaluated to address the underlying genetics of Alzheimer’s disease.
LEXEO Therapeutics today announced that the U.S. FDA has granted fast track designation to LX1001, the company’s adeno-associated virus mediated gene therapy program, for the potential treatment of apolipoprotein E4 associated Alzheimer’s disease.
